The pharmaceutical industry is increasingly turning to Bayesian methods in early phase trials in an attempt to improve efficiency and enhance decision making. One reason for this growing interest is the ability of Bayesian methods to leverage relevant external information, be this historical data or expert opinion. This 1-day scientific meeting provides an opportunity to learn about some of the main techniques for incorporating historical data into study analyses using different discounting methods, and for eliciting expert prior information in situations where no or limited historical data are available.
Further updates and exact timings to the programme will be forthcoming.
Confirmed Speakers:
Nicky Best (GSK): Prior elicitation in practice: early experiences with eliciting expert beliefs to enhance decision making in drug development
Nelson Kinnersley (Roche): Practical Considerations when Eliciting Expert Beliefs for Clinical Trial Design
Nelson will share experiences gained from conducting elicitation sessions in the clinical trial domain. Aspects of preparation, training, conducting and documenting the outcomes will be described.
Tony O’Hagan (Sheffield University): Where do we need expert judgment in drug development? ... Everywhere.
Kate Ren (Sheffield University): Elicitation in clinical trial planning: time-to-event data
Beat Neuenschwander (Novartis): Using Co-Data in Early Phase Clinical Trials: Practical and Methodological Aspects
Registration on or before 23rd July
PSI Members: £100.00 (plus VAT)
Non-Members*: £140.00 (plus VAT)
Academics*: £40.00 (plus VAT)
Registration after 23rd July
PSI Members: £140.00 (plus VAT)
Non-Members*: £200.00 (plus VAT)
Academics*: £70.00 (plus VAT)
* Price includes 1 year PSI affiliate membership
Early registration is encouraged as places are limited.
The pharmaceutical industry is increasingly turning to Bayesian methods in early phase trials in an attempt to improve efficiency and enhance decision making. One reason for this growing interest is the ability of Bayesian methods to leverage relevant external information, be this historical data or expert opinion. This 1-day scientific meeting provides an opportunity to learn about some of the main techniques for incorporating historical data into study analyses using different discounting methods, and for eliciting expert prior information in situations where no or limited historical data are available.
Further updates and exact timings to the programme will be forthcoming.
Confirmed Speakers:
Nicky Best (GSK): Prior elicitation in practice: early experiences with eliciting expert beliefs to enhance decision making in drug development
Nelson Kinnersley (Roche): Practical Considerations when Eliciting Expert Beliefs for Clinical Trial Design
Nelson will share experiences gained from conducting elicitation sessions in the clinical trial domain. Aspects of preparation, training, conducting and documenting the outcomes will be described.
Tony O’Hagan (Sheffield University): Where do we need expert judgment in drug development? ... Everywhere.
Kate Ren (Sheffield University): Elicitation in clinical trial planning: time-to-event data
Beat Neuenschwander (Novartis): Using Co-Data in Early Phase Clinical Trials: Practical and Methodological Aspects
Registration on or before 23rd July
PSI Members: £100.00 (plus VAT)
Non-Members*: £140.00 (plus VAT)
Academics*: £40.00 (plus VAT)
Registration after 23rd July
PSI Members: £140.00 (plus VAT)
Non-Members*: £200.00 (plus VAT)
Academics*: £70.00 (plus VAT)
* Price includes 1 year PSI affiliate membership
Early registration is encouraged as places are limited.
The pharmaceutical industry is increasingly turning to Bayesian methods in early phase trials in an attempt to improve efficiency and enhance decision making. One reason for this growing interest is the ability of Bayesian methods to leverage relevant external information, be this historical data or expert opinion. This 1-day scientific meeting provides an opportunity to learn about some of the main techniques for incorporating historical data into study analyses using different discounting methods, and for eliciting expert prior information in situations where no or limited historical data are available.
Further updates and exact timings to the programme will be forthcoming.
Confirmed Speakers:
Nicky Best (GSK): Prior elicitation in practice: early experiences with eliciting expert beliefs to enhance decision making in drug development
Nelson Kinnersley (Roche): Practical Considerations when Eliciting Expert Beliefs for Clinical Trial Design
Nelson will share experiences gained from conducting elicitation sessions in the clinical trial domain. Aspects of preparation, training, conducting and documenting the outcomes will be described.
Tony O’Hagan (Sheffield University): Where do we need expert judgment in drug development? ... Everywhere.
Kate Ren (Sheffield University): Elicitation in clinical trial planning: time-to-event data
Beat Neuenschwander (Novartis): Using Co-Data in Early Phase Clinical Trials: Practical and Methodological Aspects
Registration on or before 23rd July
PSI Members: £100.00 (plus VAT)
Non-Members*: £140.00 (plus VAT)
Academics*: £40.00 (plus VAT)
Registration after 23rd July
PSI Members: £140.00 (plus VAT)
Non-Members*: £200.00 (plus VAT)
Academics*: £70.00 (plus VAT)
* Price includes 1 year PSI affiliate membership
Early registration is encouraged as places are limited.
The pharmaceutical industry is increasingly turning to Bayesian methods in early phase trials in an attempt to improve efficiency and enhance decision making. One reason for this growing interest is the ability of Bayesian methods to leverage relevant external information, be this historical data or expert opinion. This 1-day scientific meeting provides an opportunity to learn about some of the main techniques for incorporating historical data into study analyses using different discounting methods, and for eliciting expert prior information in situations where no or limited historical data are available.
Further updates and exact timings to the programme will be forthcoming.
Confirmed Speakers:
Nicky Best (GSK): Prior elicitation in practice: early experiences with eliciting expert beliefs to enhance decision making in drug development
Nelson Kinnersley (Roche): Practical Considerations when Eliciting Expert Beliefs for Clinical Trial Design
Nelson will share experiences gained from conducting elicitation sessions in the clinical trial domain. Aspects of preparation, training, conducting and documenting the outcomes will be described.
Tony O’Hagan (Sheffield University): Where do we need expert judgment in drug development? ... Everywhere.
Kate Ren (Sheffield University): Elicitation in clinical trial planning: time-to-event data
Beat Neuenschwander (Novartis): Using Co-Data in Early Phase Clinical Trials: Practical and Methodological Aspects
Registration on or before 23rd July
PSI Members: £100.00 (plus VAT)
Non-Members*: £140.00 (plus VAT)
Academics*: £40.00 (plus VAT)
Registration after 23rd July
PSI Members: £140.00 (plus VAT)
Non-Members*: £200.00 (plus VAT)
Academics*: £70.00 (plus VAT)
* Price includes 1 year PSI affiliate membership
Early registration is encouraged as places are limited.
The pharmaceutical industry is increasingly turning to Bayesian methods in early phase trials in an attempt to improve efficiency and enhance decision making. One reason for this growing interest is the ability of Bayesian methods to leverage relevant external information, be this historical data or expert opinion. This 1-day scientific meeting provides an opportunity to learn about some of the main techniques for incorporating historical data into study analyses using different discounting methods, and for eliciting expert prior information in situations where no or limited historical data are available.
Further updates and exact timings to the programme will be forthcoming.
Confirmed Speakers:
Nicky Best (GSK): Prior elicitation in practice: early experiences with eliciting expert beliefs to enhance decision making in drug development
Nelson Kinnersley (Roche): Practical Considerations when Eliciting Expert Beliefs for Clinical Trial Design
Nelson will share experiences gained from conducting elicitation sessions in the clinical trial domain. Aspects of preparation, training, conducting and documenting the outcomes will be described.
Tony O’Hagan (Sheffield University): Where do we need expert judgment in drug development? ... Everywhere.
Kate Ren (Sheffield University): Elicitation in clinical trial planning: time-to-event data
Beat Neuenschwander (Novartis): Using Co-Data in Early Phase Clinical Trials: Practical and Methodological Aspects
Registration on or before 23rd July
PSI Members: £100.00 (plus VAT)
Non-Members*: £140.00 (plus VAT)
Academics*: £40.00 (plus VAT)
Registration after 23rd July
PSI Members: £140.00 (plus VAT)
Non-Members*: £200.00 (plus VAT)
Academics*: £70.00 (plus VAT)
* Price includes 1 year PSI affiliate membership
Early registration is encouraged as places are limited.
The pharmaceutical industry is increasingly turning to Bayesian methods in early phase trials in an attempt to improve efficiency and enhance decision making. One reason for this growing interest is the ability of Bayesian methods to leverage relevant external information, be this historical data or expert opinion. This 1-day scientific meeting provides an opportunity to learn about some of the main techniques for incorporating historical data into study analyses using different discounting methods, and for eliciting expert prior information in situations where no or limited historical data are available.
Further updates and exact timings to the programme will be forthcoming.
Confirmed Speakers:
Nicky Best (GSK): Prior elicitation in practice: early experiences with eliciting expert beliefs to enhance decision making in drug development
Nelson Kinnersley (Roche): Practical Considerations when Eliciting Expert Beliefs for Clinical Trial Design
Nelson will share experiences gained from conducting elicitation sessions in the clinical trial domain. Aspects of preparation, training, conducting and documenting the outcomes will be described.
Tony O’Hagan (Sheffield University): Where do we need expert judgment in drug development? ... Everywhere.
Kate Ren (Sheffield University): Elicitation in clinical trial planning: time-to-event data
Beat Neuenschwander (Novartis): Using Co-Data in Early Phase Clinical Trials: Practical and Methodological Aspects
Registration on or before 23rd July
PSI Members: £100.00 (plus VAT)
Non-Members*: £140.00 (plus VAT)
Academics*: £40.00 (plus VAT)
Registration after 23rd July
PSI Members: £140.00 (plus VAT)
Non-Members*: £200.00 (plus VAT)
Academics*: £70.00 (plus VAT)
* Price includes 1 year PSI affiliate membership
Early registration is encouraged as places are limited.
Attendance at the course counts as 7.5 hours towards any CPD requirements
Many thanks to GSK
for hosting the September event.
If you would like to host a PSI one day meeting for a topic of particular
interest to you please contact: nickm@amgen.com
(Scientific Chair) PSI
Upcoming Events
Joint PSI/EFSPI Visualisation SIG 'Wonderful Wednesday' Webinars
Our monthly webinar explores examples of innovative data visualisations relevant to our day to day work. Each month a new dataset is provided from a clinical trial or other relevant example, and participants are invited to submit a graphic that communicates interesting and relevant characteristics of the data.
The event will open with an overview on drug development in women’s health from a clinician perspective. This talk is followed by talks about statistical challenges when planning IVF studies and analysing the menstrual cycles.
This webinar will provide an overview of surrogacy for licensing and reimbursement. In turn, the need of extensions of the SPIRIT and CONSORT statement will be defined and outlined, with case studies to support.
Joint PSI/EFSPI Pre-Clinical SIG Webinar: Virtual Control Groups in Toxicity Studies
Lea Vaas will present how replacement of concurrent control animals by Virtual Control Groups (VCGs) in systemic toxicity studies may help in contributing to the 3R's principle of animal experimentation: Reduce, Refine, Replace.
Joint PSI/EFSPI Data Science SIG Webinar: Developing Digital Measures (Digital Biomarkers) in Drug Development – insights from Mobilise D consortium
We will share a brief overview of what Mobilise D is and why it is an important step stone in the development of digital biomarkers, and how Mobilise D outputs can be relevant for you.
This networking event is aimed at statisticians that are new to the pharmaceutical industry who wish to meet colleagues from different companies and backgrounds.
PSI Webinar: Development of Gene Therapies: Strategic, Scientific, Regulatory and Access Considerations
This webinar will cover the history of cell/gene therapy, major regulatory advances, the role of quantitative scientists in drug development of these novel therapeutics, and discuss opportunities for innovation and product advancement.
This networking event is aimed at statisticians that are new to the pharmaceutical industry who wish to meet colleagues from different companies and backgrounds.
PSI Introduction to Industry Training (ITIT) Course - 2024/2025
An introductory course giving an overview of the pharmaceutical industry and the drug development process as a whole, aimed at those with 1-3 years' experience. It comprises of six 2-day sessions covering a range of topics including Research and Development, Toxicology, Data Management and the Role of a CRO, Clinical Trials, Reimbursement, and Marketing.
This networking event is aimed at statisticians that are new to the pharmaceutical industry who wish to meet colleagues from different companies and backgrounds.
Statisticians in the Pharmaceutical Industry Executive Office: c/o MCI UK Ltd | Unit 24/22 South | Building 4000 | Langstone Park| Langstone Road | Havant | PO9 1SA | UK